Skip to main content
NBIX
NASDAQ Life Sciences

Neurocrine Q3 Revenue Tops $1.1B, INGREZZA Guidance Raised to $2.9-$2.925B

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Pharmaceutical Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$145.35
Mkt Cap
$14.775B
52W Low
$122.138
52W High
$186.12
52W Position info
19% above low
Off High info
22% below high
Rel. Volume info
1.6× avg
Market data snapshot near publication time

NBIX sits 19% above its 52-week low of $122.138.

Summary

Neurocrine reported Q3 2026 revenue of $1.123 billion, up 41%, with INGREZZA sales of $801 million. Full-year INGREZZA guidance rose to $2.9-$2.925 billion and SG&A guidance came down, lifting Non-GAAP EPS to $3.29 from $2.17.


Key Events · Earnings and Guidance · NBIX

  • Q3 Revenue Tops $1.1 Billion

    Total revenues reached $1,123 million versus $795 million a year earlier, 41% growth, as net product sales exceeded $1 billion for the first time.

  • INGREZZA Guidance Raised Again

    Full-year 2026 INGREZZA net sales guidance increased to $2.900-$2.925 billion from $2.825-$2.875 billion; Q3 INGREZZA sales were $801 million, up 17%.

  • SG&A Outlook Cut, EPS Jumps

    GAAP SG&A guidance was lowered to $1,540-$1,560 million and Non-GAAP to $1,290-$1,310 million; Non-GAAP diluted EPS rose to $3.29 from $2.17.

  • Cash Falls After Soleno Deal

    Cash, equivalents and marketable securities totaled $790 million at September 30, 2026 versus $2,543 million at December 31, 2025, after the May 2026 Soleno acquisition added $2.2 billion of VYKAT XR intangibles.


Analysis · NBIX · Life Sciences

For the first time, Neurocrine crossed $1 billion in quarterly net product sales, with total revenue up 41% to $1.123 billion. Full-year INGREZZA guidance was raised by $75 million at the midpoint and the SG&A outlook was cut, so more of each sales dollar reaches the bottom line — Non-GAAP EPS jumped to $3.29 from $2.17 a year ago. The offset is cash: $790 million on hand versus $2.543 billion at year-end 2025, reflecting the May 2026 Soleno acquisition and the $2.2 billion of VYKAT XR intangible now being amortized. Management pointed to 2027 Phase 3 readouts for osavampator in major depressive disorder and direclidine in schizophrenia, with an R&D Day set for December 15, 2026.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, NBIX was trading at $145.35 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $14.8B. The 52-week trading range was $122.14 to $186.12. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

NBIX - Latest Insights

NBIX
Nov 03, 2026, 2:36 PM EST
Source: Seeking Alpha
Importance Score:
7
Price at Filing: $168.29
Real-time Price: $160.53 info
Change: -$7.76 (-5%) info
Market Cap: $16.271B info
NBIX
Nov 02, 2026, 4:50 PM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $157.48
Real-time Price: $160.53 info
Change: +$3.05 (+2%) info
Market Cap: $16.271B info
NBIX
Nov 02, 2026, 4:14 PM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $146.96
Real-time Price: $160.53 info
Change: +$13.57 (+9%) info
Market Cap: $16.271B info
NBIX
Aug 26, 2026, 3:33 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $153.37
Real-time Price: $160.53 info
Change: +$7.16 (+5%) info
Market Cap: $16.271B info
NBIX
Aug 03, 2026, 7:33 AM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $167.40
Real-time Price: $160.53 info
Change: -$6.87 (-4%) info
Market Cap: $16.271B info